Ensysce Biosciences, Inc. (NASDAQ:ENSC) Sees Large Growth in Short Interest

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 6,350,000 shares, an increase of 5,514.5% from the October 15th total of 113,100 shares. Based on an average daily trading volume, of 27,160,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 43.4% of the shares of the company are short sold.

Ensysce Biosciences Stock Down 2.4 %

Ensysce Biosciences stock opened at $0.67 on Wednesday. The stock has a market cap of $5.95 million, a P/E ratio of -0.24 and a beta of 0.63. The company’s 50 day moving average price is $0.36 and its two-hundred day moving average price is $0.45. Ensysce Biosciences has a 52 week low of $0.14 and a 52 week high of $2.06.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.17. The company had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.30 million. Ensysce Biosciences had a negative net margin of 784.35% and a negative return on equity of 834.40%. On average, equities analysts anticipate that Ensysce Biosciences will post -1.43 EPS for the current year.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.